Volume 108, Issue 4 pp. 880-882

Effects of intravenous immunoglobulin in a patient with intermittent thrombotic thrombocytopenic purpura

Haruki Kondo

Haruki Kondo

Division of Haematology and Oncology, Department of Medicine, Shimizu Kohsei Hospital, Shimizu, Shizuoka, Japan

Search for more papers by this author
Takaaki Imamura

Takaaki Imamura

Division of Haematology and Oncology, Department of Medicine, Shimizu Kohsei Hospital, Shimizu, Shizuoka, Japan

Search for more papers by this author
First published: 24 December 2001
Citations: 6
Dr HarukiKondo Division of Haematology and Oncology, Department of Medicine, Shimizu Kohsei Hospital, 578-1 Ihara-cho, Shimizu City, Shizuoka (424-0114), Japan. E-mail address: [email protected]

Abstract

We describe a patient with a 9-year history of thrombotic thrombocytopenic purpura (TTP) who exhibited four relapses. Intravenous immunoglobulin (IVIg) was effective for these four episodes. The patient was well and the laboratory findings were within normal ranges between each episode, although unusually large von Willebrand factor multimers were observed during remission. Our results suggest the usefulness of IVIg at the time of relapse in the treatment of patients with TTP who have multiple relapses over a long period.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.